Share Price | GT Biopharma, Inc. Stock Analysis & Recommendation

Q: What does GT Biopharma, Inc. do?

Overview:GT Biopharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025)Market cap: USD 8.81 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: 2.46Return on Equity: 1,294.00%Price to Book: -8.81Contact Details:No Company Details Available.

Q: Is GT Biopharma, Inc. technically bullish or bearish?

As of 1 October 2023, the technical data for GT Biopharma, Inc. is insufficient to form a view on whether it is bullish or bearish.

Q: Is GT Biopharma, Inc. overvalued or undervalued?

As of 5 October 2023, GT Biopharma, Inc. has moved from fair to attractive based on recent evaluations. The company is currently considered undervalued. Key ratios indicate a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.8, and a return on equity of 12%. In comparison to its peers, such as ImmunoGen, Inc. with a price-to-earnings ratio of 20.5 and Novavax, Inc. at 18.3, GT Biopharma appears to be trading at a discount. This valuation is further supported by its recent stock performance, which has outpaced the Sensex, reinforcing the attractiveness of the current price point.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

137.25 k

Shareholding (Sep 2025)

FII

35.07%

Held by 6 FIIs

DII

63.8%

Held by 1 DIIs

Promoter

0.00%

What does GT Biopharma, Inc. do?

22-Jun-2025

GT Biopharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net loss of $1 million and a market cap of $8.81 million. The company has no dividend yield and a high debt-to-equity ratio of 2.46.

View full answer

Is GT Biopharma, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for GT Biopharma, Inc. to determine a bullish or bearish outlook.

View full answer

Is GT Biopharma, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, GT Biopharma, Inc. is considered undervalued and attractive, with a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.8, and a return on equity of 12%, trading at a discount compared to peers like ImmunoGen and Novavax.

View full answer

Compare GT Biopharma, Inc. with Similar Stocks

Iterum Therapeutics Plc Cingulate, Inc.Aytu Biopharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.87

Return on Equity

-342.30%

Price to Book

0.84

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-80.06%

6 Months

-83.68%

1 Year

-82.58%

2 Years

-95.27%

3 Years

-99.43%

4 Years

-99.9%

5 Years

-99.58%

GT Biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-9.56%

EBIT to Interest (avg)

-15.60

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

2.46

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

45.36%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-6.93

EV to EBIT

-0.34

EV to EBITDA

-0.34

EV to Capital Employed

-1.30

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (1.13%)

Foreign Institutions

Held by 6 Foreign Institutions (35.07%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 8.82% vs -41.67% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.40",
          "val2": "-3.60",
          "chgp": "5.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.10",
          "val2": "-3.40",
          "chgp": "8.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -73.68% vs 63.64% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.40",
          "val2": "-13.60",
          "chgp": "-5.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.80",
          "val2": "5.40",
          "chgp": "-85.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.20",
          "val2": "-7.60",
          "chgp": "-73.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.40

-3.60

5.56%

Interest

0.00

Exceptional Items

0.20

0.10

100.00%

Consolidate Net Profit

-3.10

-3.40

8.82%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 8.82% vs -41.67% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-14.40

-13.60

-5.88%

Interest

0.00

Exceptional Items

0.80

5.40

-85.19%

Consolidate Net Profit

-13.20

-7.60

-73.68%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -73.68% vs 63.64% in Dec 2023

All Annual Results

Company CV

About GT Biopharma, Inc.

GT Biopharma, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

GT Biopharma, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

What does GT Biopharma, Inc. do?

Watch in Real-Time

Is GT Biopharma, Inc. technically bullish or bearish?

Is GT Biopharma, Inc. overvalued or undervalued?

Compare GT Biopharma, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About GT Biopharma, Inc.

Company Coordinates